11Dec/13

Researchers Identify a New Way to Predict the Prognosis for Heart Failure Patients – Newswise (press release)


Irish Medical Times

Researchers Identify a New Way to Predict the Prognosis for Heart Failure Patients
Newswise (press release)
Newswise — Johns Hopkins researchers have identified a new way to predict which heart failure patients are likely to see their condition get worse and which ones have a better prognosis. Their study is one of the first to show that energy metabolism
New findings advance the opportunities for a ‘pacemaker in a bottle’Irish Medical Times

all 4 news articles »

11Dec/13

Idelalisib With Rituximab Boosts Survival in Relapsed CLL – Medscape

Idelalisib With Rituximab Boosts Survival in Relapsed CLL
Medscape
In a phase 3 trial, known as Study 116, the investigational agent idelalisib (under development by Gilead), when added to rituximab (Rituxan), improved outcomes in patients with relapsed CLL. “Idelalisib is a targeted, highly selective, orally
Idelalisib plus rituximab extended survival in previously treated CLLHealio
Idelalisib/Rituximab Combo Improves Survival in Late-Stage CLLCancer Network
Gilead’s Pipeline EncouragesYahoo News

all 6 news articles »

11Dec/13

Roche, Prothena Enter Into Worldwide Collaboration to Co-Develop Antibodies … – Benzinga

Roche, Prothena Enter Into Worldwide Collaboration to Co-Develop Antibodies
Benzinga
Roche (OTC: RHHBY) and Prothena Corporation plc (Nasdaq: PRTA), announced today that they have entered into a worldwide collaboration to develop and commercialize antibodies that target alpha-synuclein, including PRX002, Prothena’s monoclonal 
Roche and Prothena to Devlop Antibodies for Parkinson’s DiseasePharmaceutical Processing
Roche and Prothena Enter Into Worldwide Collaboration to Co-Develop and Co MarketWatch
Roche, Prothena ink potential $600 million deal for Parkinson’s diseaseSan Francisco Business Times (blog)
RTT News –Seeking Alpha
all 10 news articles »
11Dec/13

CCS issues guidelines to improve early diagnosis and effective treatment of … – Medical Xpress

CCS issues guidelines to improve early diagnosis and effective treatment of
Medical Xpress
The Children’s Heart Failure Study Group of the Canadian Cardiovascular Society, in collaboration with the Canadian Pediatric Cardiology Association, has developed new guidelines to assist practitioners in primary care and emergency departments to 

and more »